• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Mitochon Pharmaceuticals to support mitochondrial research in Parkinson’s

Mitochon Pharmaceuticals to support mitochondrial research in Parkinson’s

October 4, 2017
CenterWatch Staff

Mitochon Pharmaceuticals announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in ameliorating the deficits associated with dopaminergic neuron loss, the hallmark of Parkinson’s disease. If successful, Mitochon’s compounds, MP101 ad MP201 could be in patients as early as 2019.

 “We are delighted to receive funding from The Michael J. Fox Foundation, the preeminent institution in the field of Parkinson’s research. By harnessing the power of the mitochondria, our compounds are able to protect cells from the destructive effects of age-related degeneration. Importantly, this funding will pave the way for human clinical development, with the hope of helping the millions of people with Parkinson’s disease,” said Robert Alonso, co-founder and CEO of Mitochon.

“Abnormalities in the mitochondrial processes can have severe consequences for the function and survival of dopamine neurons in people with PD,” said Shalini Padmanabhan, Ph.D., Associate Director of Research Programs at MJFF. “The Foundation supports Mitochon’s work toward discovery and development of mitochondrial-targeted therapies to speed breakthroughs for patients.”

MP101 and MP201 are mitochondrial targeted, once-a-day, oral therapies that have been shown to shield cells from damage caused by a host of degenerative processes (genetic and non-genetic, auto-immune and injury). In preclinical studies, these compounds have exhibited striking protective and functional benefits in disease models. These include: brain volume sparing in Huntington’s disease; axonal protection from demyelination in Multiple Sclerosis and dopaminergic neuron loss in Parkinson’s disease. To understand the critical step of translation, Mitochon will initiate Phase I studies in normal healthy volunteers in 2018 and is expected to be in Phase II studies in 2019.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing